Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique

Progress in Brain Research

Volumn 145, Issue , 2004, Pages 301-309

  Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID; APOLIPOPROTEIN E4; CARBON 11; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; GLUCOSE; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; PHYSOSTIGMINE; RIVASTIGMINE; SCOPOLAMINE; TACRINE;

ALLELE; ALZHEIMER DISEASE; ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN REGION; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FOREBRAIN; GENETIC ASSOCIATION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HETEROZYGOTE; HUMAN; IMAGING; LONG TERM CARE; MEMORY; MENTAL PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; RECOGNITION; VISUAL INFORMATION; WORKING MEMORY;

EID: 0344009739     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(03)45021-8     Document Type: Conference Paper

References (61)

1. Almkvist, O., Basun, H., Bäckman, L., Herlitz, A., Lannfelt, L., Small, B., Viitanen, M., Wahlund, L.O. and Winblad, B. (1998) Mild cognitive impairment-an early stage of Alzheimer's disease? J. Neural Transm., 54 (suppl.): 21-29.
2. Arnáiz, E., Blomberg, M., Fernaeus, S.E., Wahlund, L.O., Winblad, B. and Almkvist, O. (2000) Psychometric discrimination of Alzheimer's disease and mild cognitive impairment. Alzheimer Report, 2: 97-201.
3. Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.O., Winblad, B., Valind, S. and Nordberg, A. (2001) Impaired cerebral metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport, 12: 851-855.
4. Bäckman, L., Almkvist, O., Andersson, J., Nordberg, A., Winblad, B., Reineck, R. and Långström, B. (1997) Brain activation in young and older adults during implicit and explicit retrieval. J. Cognitive Neurosci., 9: 378-391.
5. Bäckman, L., Andersson, J.L.R., Nyberg, L., Winblad, B., Nordberg, A. and Almkvist, O. (1999) Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology, 52: 1861-1870.
6. Cabeza, R. and Nyberg, L. (2000) Imaging cognition II. An empirical review of 275 PET and fMRI studies. J. Cognitive Neurosci., 12: 1-47.
7. Corder, E., Jelic, V., Basun, H., Lannfelt, L., Valind, S., Winblad, B. and Nordberg, A. (1997) No difference in cerebral glucose metabolism in patients with Alzheimer's disease and differing apolipoprotein E genotype. Arch. Neurol., 54: 273-277.
8. Coull, J.T., Frith, C.D., Frackowiak, R.S.J. and Grasby, P.M. (1996) A fronto-parietal network for rapid visual processing: a PET study of sustained attention and working memory. Neuropsychologia, 34: 1085-1095.
9. Court, J., Martin-Ruiz, C., Piggott, M., Spurden, D., Griffiths, M. and Perry, E.K. (2001) Nicotinic receptors abnormalities in Alzheimer's disease. Biol. Psychiatry, 49: 175-184.
10. Darreh-Shori, T., Almkvist, O., Guan, Z.Z., Garlind, A., Strandberg, B., Svensson, A.L., Soreq, M., Hellström-Lindahl, E. and Nordberg, A. (2002) Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology, 59: 563-572.
11. Davidsson, P., Blennow, K., Andreasen, N., Erikssson, B., Minthon, L. and Hesse, C. (2001) Differential increase in cerebrospinal fluid acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci. Lett., 300: 157-160.
12. Davis, D.G., Schmitt, F.A., Wekstein, D.R. and Markesbery, W.R. (1999) Alzheimer's neuropathologic alterations in aged cognitive normal subjects. J. Neuropathol. Exp. Neurol., 58: 376-388.
13. DeKosky, S.T., Ikonomovic, M.D., Styren, S.D., Beckett, L., Wisniewski, S., Bennett, D.A., Cochran, E.J., Kordower, J.H. and Mufson, E.J. (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol., 5: 145-155.
14. 11C-methyl]-benztropine. Synapse, 5: 213-223.
15. Doody, R.S., Stevens, J.C., Beck, C., Dubinsky, R.M., Kaye, J.A., Gwyther, L., Mohs, R.C., Thal, L., Whitehouse, P., DeKosky, S.T. and Cummings, J.L. (2001) Practice parameter: standard subcommittee of the American Academy of Neurology. Neurology, 56: 1154-1166.
16. Engler, H., Nordberg, A., Blomqvist, G., Bergström, M., Estrada, H., Barletta, J., Sandell, J., Antoni, G., Långström, B., Klunk, B., Debnath, M., Holt, D., Wang, Y., Huang, G. and Mathis, C. (2002) First human study with a benzothiazole amyloid imaging agent in Alzheimer's disease and control subjects. Neurobiol. Aging, 231S: 1568.
17. Flicker, C., Ferris, S.H. and Reisberg, B. (1991) Mild cognitive impairment in the elderly: predictors of dementia. Neurology, 41: 1006-1009.
18. Furey, M.L., Pietrini, P., Haxby, J.V., Alexander, G.E., Lee, H.C., VanMete, J., Grady, C.L., Shetty, U., Rapoport, S.I., Schapiro, M.B. and Freo, U. (1997) Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc. Natl. Acad. USA, 94: 6512-6516.
19. Furey, M.L., Pietrini, P. and Haxby, J.V. (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science, 290: 2315-2319.
20. Giacobini, E. (2001) Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs, 15: 85-91.
21. Goldman, W.P., Price, J.L., Storandt, M., Grant, E.A., McKee, D.W., Rubin, E.H. and Morris, J.C. (2001) Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology, 56: 361-367.
22. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297: 353-356.
23. Hirono, N., Mori, E., Yasuda, M., Ishii, K., Ikejiri, Y., Shimomura, T., Hashimoto, M., Yamashita, H. and Sasali, M. (1998) Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 12: 362-367.
24. Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K. and Irie, T. (1997) Measurement of acetylcholinesterase by positron emission tomography in the brain of healthy controls and patients with Alzheimer's disease. Lancet, 349: 1805-1809.
25. Jelic, V. and Nordberg, A. (2000) Early Diagnosis of Alzheimer's disease with positron emission tomography. Alzheimer Dis. Assoc. Disord., 14 (suppl.): S109-S113.
26. Johannsen, P., Jacobsen, J., Bruhn, P. and Gjedde, A. (1999) Cortical responses to sustained and divided attention in Alzheimer's disease. NeuroImage, 10: 269-281.
27. Knopman, D.S., DeKosky, S.T., Cummings, J.L., Corey-Bloom, J., Relkin, N., Small, G.W., Miller, B. and Stevens, J.C. (2001) Practice parameters: Diagnosis of dementia (an evidence-based review). Report of the quality standard subcommittee of the American Academy of Neurology. Neurology, 56: 1143-1153.
28. Kuhl, D.E., Minoshima, S., Fessler, J.A., Frey, K.A., Foster, N.L., Ficardo, E.P., Wiland, D.M. and Koeppe, R.A. (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol., 40: 399-410.
29. Kuhl, D.E., Koeppe, R.A., Minoshima, S., Snyder, S.E., Ficardo, E.P., Foster, N.L., Frey, K.A. and Kilbourn, M.R. (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 52: 691-699.
30. Kuhl, D.E., Minoshima, S., Frey, K.A., Foster, N.L., Kilbourn, M.R. and Koeppe, R.A. (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol., 48: 391-395.
31. Lawrence, A.D. and Sahakian, B.J. (1995) Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis. Assoc. Disord., (suppl.2): 43-49.
32. 3H]epibatidine. Brain Res., 801: 143-149.
33. Mesulam, M.-M. and Geula, C. (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol., 275: 216-240.
34. Mielke, R., Herholz, K., Grind, M., Kessler, J. and Heiss, W.D. (1994) Clinical deterioration in probable Alzheimer disease correlates with progressive metabolic impairment of association areas. Dementia, 5: 215-234.
35. Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L. and Kuhl, D.E. (1997) Metabolic reduction in the posterior cingulate cortex in the very early Alzheimer's disease. Ann. Neurol., 42: 85-94.
36. Nordberg, A. (1993) Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res., 57: 215-234.
37. Nordberg, A. (1999) Functional brain imaging in Alzheimer's disease. In: S. Gauthier (Ed.), Clinical Diagnosis and Management of Alzheimer's Disease, 2nd Edition. Martin Dunitz, London, pp. 117-132.
38. Nordberg, A. (2000a) Neuroprotection in Alzheimer's disease-new strategies in treatment. Neurotoxicity Res., 2: 157-165.
39. Nordberg, A. (2000b) The effect of cholinesterase inhibitors studied with imaging. In: E. Giacobini (Ed.), Cholinesterases and Cholinesterase Inhibitors. Martin Dunitz, London, pp. 237-247.
40. Nordberg, A. (2001) Brain functional imaging in early and preclinical Alzheimers Disease. Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biol. Psychiatry, 49: 200-210.
41. Nordberg, A. and Svensson, A.L. (1998) Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology. Drug Safety, 19: 465-480.
42. 11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord., 1: 21-27.
43. Nordberg, A., Hellström-Lindahl, E., Almkvist, O. and Meurling, L. (1999) Activities of actetylcholinesterase in CSF increase in Alzheimer patients after treatment with tacrine. Alzheimer Report, 2: 347-352.
44. Nordberg, A., Jelic, V., Arnáiz, E., Långström, B. and Almkvist, O. (2001) Title missing. In: K. Iqbal, S. Sisodia and B. Winblad (Eds.), Alzheimer's Disease: Advances in Etiology, Pathogensis and Therapeutics. John Wiley & Sons, Chichester, pp. 153-164.
45. Perry, E.K. (1986) The cholinergic hypothesis-ten years on. Br. Med. Bull., 42: 63-69.
46. Perry, R.J. and Hodges, J.R. (1999) Attention and executive deficits in Alzheimer's disease. A critical review. Brain, 122: 383-404.
47. Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.H.J., Tangalos, E.G. and Krokmen, E. (1999) Mild cognitive impairment: clinical characterisation and outcome. Arch. Neurol., 56: 303-308.
48. Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L. and DeKosky, S.T. (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the quality standard subcommittee of the American Academy of Neurology. Neurology, 56: 1133-1142.
49. Reiman, E., Caselli, R.J., Yun, L.S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S.N. and Osborne, D. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon4 allele for apolipoprotein E. New Engl. J. Med., 334: 752-758.
50. Reiman, E., Caselli, R.J., Chen, K., Alexander, G.E., Bandy, D. and Frost, J. (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 98: 3334-3339.
51. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R. and Friedhoff, L.T. (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimers disease. Neurology, 50: 136-145.
52. Sarter, M. and Bruno, J.P. (2002) Mild cognitive impairment and the cholinergic hypothesis: a very different take on recent data. Ann. Neurol., 52: 384-385.
53. Shinotoh, H., Aotsuka, A., Fukushi, K., Nagatsuka, S., Tanaka, N., Ota, T., Tanada, S. and Irie, T. (2001) Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology, 56: 408-410.
54. Small, G.W., Komo, S., La Rue, A., Saxena, S., Phelps, M.E., Mazziotta, J.C., Saunders, A.M., Haines, J.L., Pericak-Vance, M.A. and Roses, A.D. (1996) Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann. N.Y. Acad. Sci., 802: 70-78.
55. Small, G.W., Ercoli, L.M., Silverman, D.H., Huang, S.C., Komo, S., Bookheimer, S.Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N.L., Mazziotta, J.C., Saxena, S., Wu, H.M., Mega, M.S., Cummings, J.L., Saunders, A.M., Pericak-Vance, M.A., Roses, A.D., Barrio, J.R. and Phelps, M.E. (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 97: 6037-6042.
56. Snyder, S.E., Gunupudi, N., Sherman, P.S., Butch, E.R., Skaddab, M.B., Kilbourn, M.R., Koeppe, R.A. and Kuhl, D.E. (2001) Radiolabeled cholinesterase substrates: In vitro methods for determining structure-activity relationship and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. J. Cereb. Blood Flow, 21: 132-143.
57. Sperling, R., Greve, D., Dale, A., Killianty, R., Holmes, J., Rosas, D., Cocchiarella, A., Firth, P., Rosen, B., Lake, S., Lange, N., Routledge, C. and Albert, M. (2002) Functional MRI detection of pharmacologically induced memory impairment. Proc. Natl. Acad. Sci. USA, 99: 455-460.
58. Stefanova, E., Blennow, K., Almkvist, O., Hellström-Lindhal, E. and Nordberg, A. (2003) Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid(1-42) (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett., 338: 159-163.
59. Svedberg, M.M., Svensson, A.L., Johnson, M., Lee, M., Cohe, O., Court, J., Soreq, H., Perry, E.K. and Nordberg, A. (2002) Upregulation of neuronal nicotinic receptors subunits α4, β2 and α7 in transgenic mice overexpressing human acetylcholinesterase. J. Mol. Neurosci., 18: 211-222.
60. Venneri, A., Shanks, M.F., Staff, R.T., Pestell, S.J., Forbes, K.E., Gemmell, H.G. and Murray, A.D. (2002) Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport, 13: 83-87.
61. Wesnes, K., Simpson, P. and Kidd, A. (1988) An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg sc. Human Psychopharmacol., 3: 27-41.